TPC-051

TPC-051 is an investigational small molecule drug candidate being developed by Tetra Pharm Technologies for the treatment of insulin resistance. As part of Tetra Pharm's metabolic disease pipeline, TPC-051 is currently in the discovery to pre-clinical stage. The company specializes in the formulation of cannabinoid-based medicines using proprietary delivery systems designed to improve bioavailability and therapeutic efficacy. TPC-051 is intended to address metabolic dysfunction, likely by modulating pathways within the endocannabinoid system that regulate glucose metabolism and insulin sensitivity, although its specific molecular target has not been publicly disclosed.